NexImmune to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel on “Expanding the Possible with Next-Generation Cell Therapies”
18 janv. 2022 16h01 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory Board
05 janv. 2022 16h01 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma
12 déc. 2021 15h40 HE
|
NexImmune, Inc.
Initial Phase 1/2 data presented at the 63rd American Society of Hematology (ASH) Annual Meeting and ExpositionPhase 1/2 study of NEXI-002 as a monotherapy in patients with relapsed/refractory...
NexImmune Reports Third Quarter 2021 Financial Results and Provides Business Updates
12 nov. 2021 07h30 HE
|
NexImmune, Inc.
Advancing two lead product candidates in Phase 1/2 clinical trials Additional clinical and preclinical data anticipated by year end 2021 and first half 2022Announced collaboration with Yale University...
NexImmune to Announce Third Quarter 2021 Financial Results and Provide Corporate Update on November 12, 2021
08 nov. 2021 16h01 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Nov. 08, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune to Present at The Society for Immunotherapy of Cancer 36th Anniversary Annual Meeting
03 nov. 2021 08h00 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune to Present at the 2021 Cantor Virtual Global Healthcare Conference
27 sept. 2021 16h01 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
10 sept. 2021 09h11 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Sept. 10, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Reports Second Quarter 2021 Financial Results and Provides Business Updates
09 août 2021 16h05 HE
|
NexImmune, Inc.
Announcing first solid tumor indication in HPV associated-malignancies – NEXI-003Advancing two lead product candidates in Phase 1/2 clinical trials Additional clinical and preclinical data anticipated...
NexImmune to Explore the Use of AIM™ Direct Injection Technology in Type 1 Diabetes
09 août 2021 16h01 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...